Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • Addressing the most neglected diseases through an open research model: the discovery of fenarimols as novel drug candidates for eumycetoma
  • Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind
  • In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series

RSS PRESS RELEASES

  • DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients
  • Drug approved in Argentina for treatment of Chagas disease in children
  • Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa

RSS NEWS

  • DNDi and GARDP Call for Nominations for Treasurer of their Boards of Directors
  • The disease that strikes back
  • Ending the Neglect of Chagas in Colombia

RSS IN THE MEDIA

  • Global Citizen: “How Switzerland is leading the fight against neglected tropical diseases”
  • Bangkok Post: “Low-cost Hep C cure showing good results”
  • Daily News: “ไทยเจ๋ง!ช่วยผู้ป่วยไวรัสตับอักเสบซีหายขาดเกือบ100%”

RSS EVENTS

  • 11th DNDi Partners’ Meeting: From innovation to access in Africa – the way forward
  • 14th ICOPA: International Congress of Parasitology
  • 22nd International AIDS Conference

RSS Scientific Articles

  • Addressing the most neglected diseases through an open research model: the discovery of fenarimols as novel drug candidates for eumycetoma
  • Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind
  • In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series
  • Report of the first international workshop on onchocerciasis-associated epilepsy

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

 

Subscribe

Sign up for the E-news newsletter

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

Graphic of DNDi's social mission ratio

  • TERMS OF USE
  • PRIVACY POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. Read cookie policy. Close